Endo Launches "Steve's Journey," the First Branded Dupuytren's Contracture Commercial for XIAFLEX® (collagenase clostridium histolyticum)
Endo (OTCQX: NDOI) has launched 'Steve's Journey,' its first branded TV commercial for XIAFLEX®, the only FDA-approved nonsurgical treatment for Dupuytren's contracture. The campaign features a real patient, Steve, and his wife Gisele, sharing their experience with the progressive hand condition that affects an estimated 17 million Americans.
The commercial showcases Steve's treatment journey with XIAFLEX® and demonstrates how the treatment helped him regain hand functionality for everyday activities. The 60-second spot will air across various platforms, including news, sports programming, popular TV series, cable channels, and streaming services.
The campaign builds on Endo's research showing that many patients delay treatment due to concerns about surgery. According to company data, patients who ask for XIAFLEX® by name receive the medication more than half of the time.
Endo (OTCQX: NDOI) ha lanciato 'Il Viaggio di Steve', il suo primo spot pubblicitario a marchio per XIAFLEX®, l'unico trattamento non chirurgico approvato dalla FDA per la contrattura di Dupuytren. La campagna presenta un paziente reale, Steve, e sua moglie Gisele, che condividono la loro esperienza con questa condizione progressiva della mano che colpisce circa 17 milioni di americani.
Lo spot pubblicitario illustra il percorso di trattamento di Steve con XIAFLEX® e dimostra come il trattamento lo abbia aiutato a riacquistare la funzionalità della mano per le attività quotidiane. Il video di 60 secondi sarà trasmesso su varie piattaforme, tra cui notizie, programmi sportivi, serie TV popolari, canali via cavo e servizi di streaming.
La campagna si basa sulla ricerca di Endo che mostra come molti pazienti ritardino il trattamento a causa di preoccupazioni riguardo all'intervento chirurgico. Secondo i dati dell'azienda, i pazienti che chiedono XIAFLEX® per nome ricevono il farmaco più della metà delle volte.
Endo (OTCQX: NDOI) ha lanzado 'El Viaje de Steve', su primer comercial de televisión de marca para XIAFLEX®, el único tratamiento no quirúrgico aprobado por la FDA para la contractura de Dupuytren. La campaña presenta a un paciente real, Steve, y su esposa Gisele, compartiendo su experiencia con esta condición progresiva de la mano que afecta a aproximadamente 17 millones de estadounidenses.
El comercial muestra el recorrido de tratamiento de Steve con XIAFLEX® y demuestra cómo el tratamiento le ayudó a recuperar la funcionalidad de la mano para actividades cotidianas. El spot de 60 segundos se emitirá en varias plataformas, incluidas noticias, programación deportiva, series de televisión populares, canales de cable y servicios de streaming.
La campaña se basa en la investigación de Endo que muestra que muchos pacientes retrasan el tratamiento debido a preocupaciones sobre la cirugía. Según los datos de la empresa, los pacientes que piden XIAFLEX® por su nombre reciben el medicamento más de la mitad de las veces.
Endo (OTCQX: NDOI)는 XIAFLEX®의 첫 번째 브랜드 TV 광고 '스티브의 여정'을 출시했습니다. 이는 듀푸이트렌 구축증에 대한 FDA 승인 비수술 치료법입니다. 이 캠페인은 실제 환자인 스티브와 그의 아내 기젤이 약 1,700만 명의 미국인에게 영향을 미치는 진행성 손 질환에 대한 경험을 공유합니다.
광고는 스티브의 XIAFLEX® 치료 여정을 보여주며, 치료가 그가 일상 활동을 위해 손 기능을 회복하는 데 어떻게 도움이 되었는지를 보여줍니다. 60초 분량의 광고는 뉴스, 스포츠 프로그램, 인기 TV 시리즈, 케이블 채널 및 스트리밍 서비스 등 다양한 플랫폼에서 방송될 예정입니다.
이 캠페인은 많은 환자가 수술에 대한 우려로 치료를 지연한다는 Endo의 연구를 바탕으로 합니다. 회사 데이터에 따르면, XIAFLEX®를 이름으로 요청한 환자는 50% 이상의 경우 약물을 받게 됩니다.
Endo (OTCQX: NDOI) a lancé 'Le Voyage de Steve', son premier spot publicitaire de marque pour XIAFLEX®, le seul traitement non chirurgical approuvé par la FDA pour la contracture de Dupuytren. La campagne met en avant un patient réel, Steve, et sa femme Gisele, partageant leur expérience avec cette maladie progressive de la main qui touche environ 17 millions d'Américains.
Le spot publicitaire présente le parcours de traitement de Steve avec XIAFLEX® et montre comment le traitement l'a aidé à retrouver la fonctionnalité de sa main pour les activités quotidiennes. Le spot de 60 secondes sera diffusé sur diverses plateformes, y compris les actualités, les programmes sportifs, les séries télévisées populaires, les chaînes câblées et les services de streaming.
La campagne s'appuie sur les recherches d'Endo montrant que de nombreux patients retardent le traitement en raison de préoccupations concernant la chirurgie. Selon les données de l'entreprise, les patients qui demandent XIAFLEX® par son nom reçoivent le médicament plus de la moitié du temps.
Endo (OTCQX: NDOI) hat 'Steves Reise' gestartet, seinen ersten Marken-TV-Werbespot für XIAFLEX®, die einzige von der FDA zugelassene nicht-chirurgische Behandlung für die Dupuytren-Kontraktur. Die Kampagne zeigt einen echten Patienten, Steve, und seine Frau Gisele, die ihre Erfahrungen mit dieser fortschreitenden Handerkrankung teilen, die schätzungsweise 17 Millionen Amerikaner betrifft.
Der Werbespot zeigt Steves Behandlungsweg mit XIAFLEX® und demonstriert, wie die Behandlung ihm geholfen hat, die Handfunktionalität für alltägliche Aktivitäten zurückzugewinnen. Der 60-sekündige Spot wird auf verschiedenen Plattformen ausgestrahlt, einschließlich Nachrichten, Sportprogrammen, beliebten TV-Serien, Kabelkanälen und Streaming-Diensten.
Die Kampagne baut auf Endos Forschung auf, die zeigt, dass viele Patienten die Behandlung aufgrund von Bedenken hinsichtlich einer Operation verzögern. Laut Unternehmensdaten erhalten Patienten, die XIAFLEX® namentlich anfordern, in mehr als der Hälfte der Fälle das Medikament.
- XIAFLEX® is the only FDA-approved nonsurgical treatment for Dupuytren's contracture
- Large market potential with 17 million Americans affected by the condition
- Over 50% success rate in receiving medication when patients request XIAFLEX® by name
- Product carries risk of tendon/ligament damage
- Potential for allergic reactions to the treatment
- Campaign builds on the momentum of Endo's disease awareness efforts.
- Commercial features a real patient—who was an untreated patient in a prior Endo video series—and his wife, sharing their personal experience with the condition and the patient's treatment with XIAFLEX®.
- Dupuytren's contracture is a progressive hand condition affecting an estimated 17 million Americans, making it likely that most people know someone who has been impacted.
Dupuytren's contracture is a progressive hand condition in which a collagen rope-like cord forms beneath the skin of the palm, pulling fingers inward toward the palm.1,2 It affects an estimated 17 million Americans.3,4*
"Those with the best understanding of Dupuytren's contracture are patients who have faced similar challenges and uncertainties," said Justin Mattice, Vice President & General Manager, Branded Specialty at Endo. "By spotlighting authentic experiences like Steve's, we are emboldening patients to connect with a hand specialist and ask for nonsurgical XIAFLEX®, positioning them as knowledgeable decision makers."
Do not receive XIAFLEX® if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX®, or to any other collagenase product. Please note that, receiving an injection of XIAFLEX® may cause damage to a tendon or ligament in your hand and cause it to break or weaken.
Steve's Sequel
This isn't Steve's first time in the spotlight. Endo's Coffee & Cords video series featured five patients at different points in their treatment journeys, and Steve lent his perspective as an untreated Dupuytren's contracture sufferer. After Coffee & Cords wrapped, Steve chose to get treated with XIAFLEX®.
Steve's Journey revisits Steve's experience with the condition, and it highlights his treatment and recovery. The campaign also incorporates the partner perspective by including Steve's wife, Gisele.
"Endo is passionate about using firsthand experiences to amplify the voices of real-life patients," noted Dayna Sracic, Executive Director, Consumer Marketing at Endo. "By sharing these powerful, personal stories, we believe we can inspire and educate others regarding Dupuytren's contracture and nonsurgical treatment with XIAFLEX®."
Insights-Driven Campaign
Endo's own research and consumer insights show many Dupuytren's contracture patients delay treatment due to concerns about surgery, often adapting to the condition instead.5†
The branded approach puts patients in the driver's seat, giving them the knowledge and product name for a nonsurgical option. Endo's research indicates that Dupuytren's contracture patients that ask for XIAFLEX® by name receive the medication more than half of the time.
Patient-Centric Campaign Creative
The commercial opens with a close-up of Steve's hand, as he and Gisele describe how Dupuytren's contracture made everyday tasks difficult. The scene transitions to them holding hands, with Steve—now treated with XIAFLEX®—expressing how much he missed this simple intimacy with his wife. Additional shots show Steve's hands-on approach to life: working on a laptop, placing his hand flat on a table, flexing it while driving, and enjoying outdoor activities with Gisele.
These moments demonstrate how XIAFLEX® has helped Steve regain the freedom to live life on his own terms. Through Steve's Journey, Endo aims to help more Americans living with Dupuytren's contracture by showcasing the outcomes of patients who have completed their nonsurgical treatment journey with XIAFLEX®.
Underscoring the desire of many patients to lead a hands-on life, the campaign drives to HandsOnLife.com.
Media Buy
The 60-second spot will air during a variety of programming, including news, sports (e.g., NASCAR and NCAA basketball), and popular TV series across networks (e.g., Survivor and Matlock), as well as on cable channels (e.g., History and Discovery), on streaming services like Hulu and Amazon, and online.
About Dupuytren's Contracture
Dupuytren's contracture is a lifelong condition that may get worse over time. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm so they can't be straightened. As Dupuytren's contracture progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities.1,2
WHAT IS XIAFLEX®?
XIAFLEX is a prescription medicine used to treat adults with Dupuytren's contracture when a "cord" can be felt. It is not known if XIAFLEX is safe and effective in children under the age of 18.
IMPORTANT SAFETY INFORMATION FOR XIAFLEX
Do not receive XIAFLEX if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX.
XIAFLEX can cause serious side effects, including:
- Tendon rupture or ligament damage. Receiving an injection of XIAFLEX may cause damage to a tendon or ligament in your hand and cause it to break or weaken. This could require surgery to fix the damaged tendon or ligament. Call your healthcare provider right away if you have trouble bending your injected finger (towards the wrist) after the swelling goes down or you have problems using your treated hand after your follow-up visit
- Nerve injury or other serious injury of the hand. After finger procedures, some people developed tears in the skin (lacerations), and local skin and soft-tissue necrosis (death of skin cells). Some lacerations and necrosis required skin grafting, or other surgery including amputation. Call your healthcare provider right away if you get numbness, tingling, increased pain, or tears in the skin (laceration) in your treated finger or hand after your injection or after your follow-up visit
- Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX because it contains foreign proteins. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:
- hives
- swollen face
- breathing trouble
- chest pain
- low blood pressure
- dizziness or fainting
- Fainting. Fainting (passing out) or near fainting can happen in people who receive XIAFLEX, especially following finger procedures
If you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away. - Increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you.
Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, or have a bleeding problem or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner. Ask your healthcare provider or pharmacist for a list of these medicines if you are unsure.
The most common side effects with XIAFLEX for the treatment of Dupuytren's contracture include:
- swelling of the injection site or the hand
- bruising or bleeding at the injection site
- pain or tenderness of the injection site or the hand
- swelling of the lymph nodes (glands) in the elbow or armpit
- itching
- breaks in the skin
- redness or warmth of the skin
- pain in the armpit
Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist.
Rx Only
Click for full Prescribing Information, including Medication Guide.
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Mattice and Ms. Sracic and any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the
*Dupuytren's contracture prevalence estimation calculation: average Dupuytren's contracture prevalence in the US (
†Data sourced from 2024 consumer market research based on a web-based survey of 200 adults who were either diagnosed with Dupuytren's contracture or believe they have Dupuytren's contracture based on a detailed description of symptoms.
References
- Hurst, LC, Badalamente, MA, et al. New England Journal of Medicine.2009;361(10),968-979.
- Bayat, A, McGrouther, DA. Annals of the Royal College of Surgeons of
England . 2006;88(1),3-8. - "How common is Dupuytren disease?" Dupuytren Research Group. April 1, 2017. Accessed January 13, 2025. https://dupuytrens.org/faq
- "
U.S. and world population clock."U.S. Census Bureau. Updated April 13, 2023. Accessed January 13, 2025. https://www.census.gov/popclock - "Dupuytren's contracture consumer awareness trial usage online survey report." Endo
USA , Inc. 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-launches-steves-journey-the-first-branded-dupuytrens-contracture-commercial-for-xiaflex-collagenase-clostridium-histolyticum-302377667.html
SOURCE Endo, Inc.
FAQ
What is the target market size for NDOI's XIAFLEX treatment?
What are the success rates for patients requesting XIAFLEX by name?
Where will NDOI's new Steve's Journey commercial be aired?
What are the main risks associated with NDOI's XIAFLEX treatment?
